Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
MWN-AI** Summary
Gelteq Limited, a Melbourne-based biotechnology company, recently announced promising preclinical study results highlighting its innovative gel-based oral delivery system for oil-soluble and poorly soluble drugs. The findings reveal significant enhancements in bioavailability and absorption rates due to Gelteq's proprietary gel platform, which addresses a critical issue in pharmaceutical development.
In two preclinical studies, the gel demonstrated a remarkable 300 percent increase in the bioavailability of an oil-soluble compound within the first hour compared to an existing FDA-approved reference product, ensuring quicker therapeutic action. Over a 24-hour period, the overall absorption improved by more than 20 percent, underscoring the gel's effectiveness in delivering lipophilic compounds while minimizing the use of emulsifiers.
Gelteq’s gel platform excels in controlled gastrointestinal transit, targeted release, and efficient absorption, as evidenced by its ability to uniformly distribute the active pharmaceutical ingredients (APIs) in the small intestine. This unique property enhances absorption through mucosal interactions across a larger intestinal surface area. Additionally, the gel formulation supports rapid absorption without compromising safety, effectively dispersing and clearing to the large intestine.
These results position Gelteq as a significant player in overcoming the challenges of solubility that affect over 40 percent of approved drugs and up to 90 percent of developmental candidates. With substantial implications for therapeutic areas such as neurology, oncology, and cardiovascular medicine, Gelteq's platform offers a versatile alternative to traditional oral delivery methods. The findings signal potential partnerships with pharmaceutical and nutraceutical companies seeking innovative solutions to reformulate existing products and tackle complex formulation challenges, positioning Gelteq as a valuable asset in drug delivery advancements.
MWN-AI** Analysis
Gelteq Limited's recent preclinical study results position the company as a notable player in the drug delivery market, particularly for oil-soluble and poorly soluble drugs. The demonstration of a 300% increase in bioavailability within the first hour and a more than 20% overall absorption improvement over a 24-hour period compared to existing FDA-approved reference products is a significant breakthrough. This level of enhancement addresses a longstanding challenge in pharmaceutical development, making Gelteq's gel-based platform a compelling alternative for companies facing solubility issues.
Investors should consider several factors when evaluating Gelteq's market potential. Firstly, the gel's ability to facilitate targeted release and enhanced absorption positions it as a promising solution for a wide range of therapeutic areas, including neurology, oncology, and cardiovascular medicine. With over 40% of approved drugs struggling with solubility, Gelteq's technology is timely and could potentially unlock previously sidelined candidates, attracting interest from major pharmaceutical companies looking to reformulate existing assets.
Moreover, the company’s focus on safety and compatibility with oral administration enhances its attractiveness to pharmaceutical and nutraceutical partners, thereby widening its market applicability. As more companies seek innovative delivery systems to improve patient compliance and therapeutic effectiveness, Gelteq's gel-based platform could experience heightened demand.
However, potential investors should remain cautious. Gelteq, while promising, operates in a competitive landscape filled with established players. Continuous investment in research and development, coupled with successful transitions from preclinical to clinical stages, will be crucial for long-term success. Therefore, while Gelteq represents an exciting opportunity, vigilance regarding market dynamics and ongoing developments is advised before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical development and demonstrate that Gelteq’s technology can enhance the oral delivery of oil-soluble and poorly soluble drugs.
Across two complementary preclinical studies, the results showed a more rapid absorption of an oil soluble compound in Gelteq’s gel base compared to an existing FDA approved reference product, with a 300 percent increase in bioavailability across the first hour. High bioavailability in the first hour is critical for rapid onset of action.
Further results demonstrated that the oil soluble compound wasn’t just more rapidly absorbed in Gelteq’s gel base, but the overall absorption was also improved. Over 24 hours, the absorption was improved by more than 20 percent overall compared to an existing FDA approved reference product. These findings further illustrate that Gelteq’s gel matrix can support the delivery of lipophilic compounds whilst moderating the need for high levels of emulsifiers.
The study results also demonstrate that Gelteq’s platform enables controlled movement through the digestive system, targeted release, and effective absorption while maintaining full clearance of both the active pharmaceutical ingredients (API) and the gel material itself.
The GI transit evaluation demonstrated that the gel disperses the active ingredient uniformly along the small intestine. This extended distribution behaviour supports improved absorption through both mucoadhesive interactions and the presentation of the drug across a larger intestinal surface area.
The studies also showed that the gel can be formulated to allow efficient transit and rapid early absorption of the API. The gel’s structural matrix dispersed and cleared effectively to the large intestine, reinforcing the platform’s safety and compatibility with oral administration.
These combined findings highlight Gelteq’s potential to provide a new and more versatile alternative to existing oral delivery approaches for oil-soluble and poorly soluble drugs.
With more than 40 percent of approved drugs and up to 90 percent of developmental candidates affected by poor solubility and bioavailability, the industry continues to invest billions of dollars 1 annually in new technologies to overcome these issues. Gelteq’s platform offers a streamlined solution that may reduce developmental burdens, enhance bioavailability, and open pathways to revive previously shelved or challenging molecules.
Therapeutic areas most likely to benefit from Gelteq’s gel-based delivery system include neurology, inflammation and pain management, hormonal therapies, cardiovascular medicine, nutraceuticals, weight management, oncology and veterinary health - categories where lipid-based or poorly soluble APIs are common and where improved absorption could meaningfully enhance clinical performance.
By enabling more consistent absorption, targeted delivery, reduced excipient reliance, and strong safety characteristics, the gel-based delivery system positions Gelteq as a valuable development partner for pharmaceutical and nutraceutical companies seeking to reformulate existing assets or address complex formulation challenges in their pipelines.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq specializes in the formulation, development and manufacturing of gel products for licensed partners across pharmaceutical, consumer health and animal health markets. The proprietary formulation technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit www.gelteq.com .
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
_________________________
1 Solubility Enhancement Excipients Market Size 2025-2032
FAQ**
How does Gelteq Limited's proprietary gel platform enhance the bioavailability of oil-soluble and poorly soluble drugs, distinguishing it from competitors in the biopharmaceutical market, particularly for those trading under "Gelteq Limited GELS"?
With more than 40 percent of approved drugs affected by poor solubility, what strategies will Gelteq Limited implement to capture market share among pharmaceutical companies facing these challenges, specifically related to "Gelteq Limited GELS"?
In what therapeutic areas does Gelteq Limited plan to focus its gel-based delivery system, and how does this align with current market demands for improved drug and nutrient bioavailability, particularly for investors interested in "Gelteq Limited GELS"?
What specific partnerships or collaborations is Gelteq Limited seeking to establish in the pharmaceutical and nutraceutical sectors to effectively utilize its gel-based technology, and how might these efforts impact the company's stock performance as "Gelteq Limited GELS"?
**MWN-AI FAQ is based on asking OpenAI questions about Gelteq Limited (NASDAQ: GELS).
NASDAQ: GELS
GELS Trading
-7.86% G/L:
$0.7003 Last:
42,499 Volume:
$0.74 Open:
